Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinicalâ„¢ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
(Date:10/27/2014)... Mass. , Oct. 27, 2014 ... "Company"), a worldwide leader in the development and ... the life sciences research market, today announced that ... presented a novel, accurate, highly reproducible, and robust ... – routine high-throughput protein analysis on small needle ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4SoundConnect Unveils Q4 Partner Incentives 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... At the 44th Annual Meeting of,the American Society ... the potential utility of Zevalin(R) (Ibritumomab,Tiuxetan) radioimmunotherapy as ... chemotherapy in the treatment of non-Hodgkin,s,lymphoma (NHL). Cell ... markets,Zevalin in the United States., "These two ...
... CITY, China, May 30 /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, ... which develops, manufactures, and markets generic and branded,bio-pharmaceutical ... 30, 2008,it closed its recently announced financing, issuing ... price of $2.00 per share and three-year warrants,to ...
... PRINCETON, N.J., May 30 Pharmacopeia (Nasdaq:,PCOP), an ... small,molecule therapeutics, announced today that it is implementing ... its resources on the company,s clinical,and later-stage discovery ... approximately 15 percent through attrition and,termination of positions ...
Cached Biology Technology:Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 2Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 3Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 4China Pharma Holdings, Inc. Closes $10 Million Financing 2China Pharma Holdings, Inc. Closes $10 Million Financing 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 2Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 4
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... Genomics of the Kidney consortium ( CAGEKID ) ... exposure to aristolochic acid, an ingredient in some ... Communications , have important implications for public health. ... every year, and in Central Europe incidence rates ... International Cancer Genome Consortium (ICGC), has been studying ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... amphibians developed the ability to feed on land before ... University report this week in the Proceedings of the ... on analysis of the skulls of the first amphibians, ... ancestors. The shapes of the junctions between adjacent skull ...
... Atlantic Ocean doesn't receive the mother lode of fixed nitrogen, ... for fathom, the Pacific and Indian oceans experience twice the ... the Jan. 11 issue of Nature. , The title of ... for N2 Fixation in all the Wrong Places." ...
... Why have large outbreaks of Ebola virus killed tens ... decade? Observations published in the May issue of The ... be amplified by Ebola transmission between ape social groups. ... control the devastating impact of Ebola on wild apes. ...
Cached Biology News:Ancient amphibians evolved a bite before migrating to dry land 2New findings blow a decade of assumptions out of the water 2New findings blow a decade of assumptions out of the water 3Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Potassium Channel kv3.2...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
MAb to Vasopressin Preservative: NaN3...
Biology Products: